|Application No.||Application Title||Issue Date|
|20140046067||PHARMACOLOGICALLY ACTIVE ALICYCLIC N,N'-SUBSTITUTED 3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND DRUGS BASED THEREON|
The invention relates to novel alicyclic N,N′-substituted diazabicyclo[3.3.1]nonane derivatives of general formula (I) which act as allosteric AMPA receptor modulators, and to drugs based thereon which can be used for treating Alzheimer's, Parkinson's and other neurod...
Novel hetaryl-[1,8]naphthyridine derivatives of formula (I)
wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP co...
|20140038943||SEROTONIN RECEPTOR MODULATOR|
Certain biphenyic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases....
|20140031348||HETEROARYL SULFONAMIDES AND CCR2/CCR9|
Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pha...
|20140024646||OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2|
The present invention comprises compounds of Formula (I).
wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specificatio...
|20140018533||NOVEL FURANONE DERIVATIVE|
To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I):
wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen...
The present invention relates to a method of controlling plants or inhibiting plant growth which comprises applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula (I)
|20140005165||SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS|
Disclosed are CCR2 antagonists of Formula (I) or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat di...
|20130345254||CYCLOHEXANE SUBSTITUTED AMINO CYCLOPENTANE DERIVATIVES AS USEFUL CCR2 ANTAGONISTS|
Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salts thereof, wherein A, B, R, and R6 are as defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and composi...
|20130345120||PEPTIDE DEFORMYLASE INHIBITORS|
The present invention relates to a compound of Formula (I):
|20130343992||RADIOLABELED PDE10A LIGANDS|
Compounds of formula (I) are disclosed
Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also us...
The invention in one embodiment is directed to a compound of Formula A:
as defined herein, or a pharmaceutically acceptable salt thereof....
|20130317057||ALDOSTERONE SYNTHASE INHIBITORS|
The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are ...
|20130317213||Hepatitis C Virus Inhibitors|
The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection....
|20130310365||CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2|
The present invention comprises compounds of Formula I.
wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventi...
Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours....
|20130310417||Small Molecules For Endothelial Cell Activation|
The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same....
|20130296333||HEDGEHOG PATHWAY MODULATORS|
The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgeh...
|20130296300||QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS|
The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J1, Ja, Jb, R2, R3, R22, Ra, Rb, Rc
Compounds disclosed herein including compounds of formula I′:
and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed h...
|20130253186||HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS|
Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schiz...
|20130244996||BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION|
The present invention relates to compounds of formula (I):
wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A...
|20130245062||NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS|
Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I
and the pharmaceutically acceptable salts ...
The present invention relates to compounds of formulae I and II
wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate,...
The present invention provides, for example, the following compound:
|20130210818||Novel Heterocyclic Compounds and Uses Thereof|
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for t...
|20130210857||Inhibitors of Human Immunodeficiency Virus Replication|
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods ...
|20130203756||ISOINDOLINE PDE10 INHIBITORS|
The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for tr...
|20130184253||TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS|
The present invention provides a compound of formula I:
|20130178458||SUBSTITUTED (1-(METHYLSULFONYL)AZETIDIN-3-YL)(HETEROCYCLOALKYL)METHANONE ANALOGS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE M1 RECEPTORS|
In one aspect, the invention relates to substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs, derivatives thereof, and related compounds, which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1
|20130165473||Azaquinolinone Derivatives and Uses Thereof|
The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient....
|20130150339||Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors|
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.
The compounds are useful for t...
|20130143899||COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS|
The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such co...
|20130131342||AGENT EXHIBITING THE PROPERTIES OF A COGNITIVE FUNCTION PROMOTER (EMBODIMENTS)|
The present invention relates to the field of chemical-pharmaceutical industry and medicine. An agent, exhibiting the properties of a cognitive function promoter, was selected from 1,3-dimethyl-5-[(4-pyridylamino)methylene]barbituric acid and 4-amino-1-(3 -nitro-2-oxo-1...
|20130123244||Hetero-Bicyclic Derivatives as HCV Inhibitors|
Inhibitors of HCV replication of formula I
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R′ have the meaning as defined herein.
|20130115193||Hepatitis C Virus Inhibitors|
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection...
|20130102611||IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS|
The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal ...
|20130102603||2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER|
The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibi...
|20130096122||FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS|
The present invention relates to sodium channel inhibitors of Formula I:
in which R1, R2, R3, R4, R5, R6, and R7 are as defined abo...
|20130079365||NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES|
The invention provides novel compounds having the general formula (I)
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9